Abstract: An optical system includes an optical resonant cavity, an optical source, an optical detector, and a signal processing circuit. The optical source is arranged to provide a source beam of light to be at least partially coupled into the optical resonant cavity. The optical detector is arranged to detect light from the source beam of light after the source beam of light has coupled into the optical resonant cavity to provide a detection signal. The signal processing circuit is configured to communicate with the optical detector to receive the detection signal. The optical resonant cavity has a bioconjugatable lipid membrane on a surface thereof. The bioconjugatable lipid membrane is functionalized to capture a specific biomolecule, and the signal processing circuit is further configured to determine a presence of the specific biomolecule when captured by the functionalized bioconjugatable lipid membrane based on processing the detection signal.

Abstract: Microarray platforms and methods of fabricating said microarrays without traditional high aspect ratio barriers used to define individual array elements are described herein. Self-assembled nanoshells were stabilized with a polymerized scaffold to enhance the stability in physiological conditions and serve as an optical transducer upon molecular recognition events. Soft photolithography combined with surface chemistry was developed for covalent immobilization of nanoshells onto the pre-patterned arrayed microspots for rapid multiplexed detection of membrane-binding analytes. This robust fabrication methodology is amenable for general lipid structures, and thus facilitates the integration of stable membrane architectures into diagnostic and prognostic platforms. In particular, the microarray platform may be used in diverse applications ranging from the detection of pathogens, such bacterial toxin in biological matrices, to cellular membrane studies.

Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

Abstract: A system and method for broadcasting a message to multiple contacts in a list of contacts provided by an electronic mail application and furnishing presence information for contacts in the list of contacts provided by the electronic mail application includes an interface for adding functionality to an electronic mail application which supports instance messaging (IM). The interface interfaces with a distributed presence enabled communication platform for providing presence information regarding contact availability. The electronic mail application utilizes the interface for displaying the contact presence information and broadcasting a message to multiple contacts in the list of contacts.

Abstract: The present invention is directed to compounds of Formula (I) and Formula (II) (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Abstract: The present invention is directed to compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

Abstract: A system and method for broadcasting a message to multiple contacts in a list of contacts provided by an electronic mail application and furnishing presence information for contacts in the list of contacts provided by the electronic mail application includes an interface for adding functionality to an electronic mail application which supports instance messaging (IM). The interface interfaces with a distributed presence enabled communication platform for providing presence information regarding contact availability. The electronic mail application utilizes the interface for displaying the contact presence information and broadcasting a message to multiple contacts in the list of contacts.

Abstract: The present invention is directed to compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

Abstract: A wafer-disposition method and apparatus are disclosed where the disposition is based on a model of systematic misalignment errors. The method comprises the steps of: modeling the misalignment errors between the mask and wafer as a mathematical model using measured misalignment data, generating a confidence limit of the probability of defect for the wafer, and determining whether the wafer satisfies a predetermined product quality level by comparing the confidence limit to the tolerance specification for the wafer. The misalignment model includes systematic errors and is represented by a polynomial based on the location of test points on the wafer. Preferably, several polynomials are formed and one that best predicts new misalignment data is selected. The confidence limit is created by combining the estimated probabilities of defect for all sliders in the wafer. Also, the product quality determination is based on a variable acceptance sampling procedure using the mathematical model.

Abstract: A method is provided for use in a Token ring network including a plurality of stations serially connected by a transmission medium so as to form a closed loop on which packets of data are circulated, wherein each respective station includes a media access controller and a buffer memory, the method including the steps of transferring data of a respective packet from a media access controller to a buffer memory; storing the data in a sequence of contiguous memory locations in the buffer memory; in the course of the step of transferring the data, generating status information for the data; after said step of storing the data, storing the status information in the buffer memory contiguously with the stored data at the beginning of the sequence of memory locations in which the data are stored.